步長製藥(603858.SH):子公司咪達那新片獲批臨牀試驗
格隆匯11月25日丨步長製藥(603858.SH)宣佈,公司全資子公司山東步長神州製藥有限公司近日收到國家藥品監督管理局核准簽發的關於咪達那新片的《藥物臨牀試驗批准通知書》。
咪達那新片主要適用於治療膀胱過度活動症的尿意急迫感、尿頻以及急迫性尿失禁,是由日本小野藥品工業株式會社和日本杏林製藥株式會社共同開發,於2007年在日本上市。咪達那新片2019年全球銷售額約3400萬美元。截至目前,公司在咪達那新片上投入的研發費用約為2178萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.